Core Insights - The article highlights the recognition of Yaoshi Bang as a leading digital comprehensive service platform in China's out-of-hospital pharmaceutical industry, awarded for its excellence in the health sector during the 2025 Capital Market Honor Ceremony [1][2] Company Overview - Yaoshi Bang was established in 2015 and aims to empower participants in the out-of-hospital pharmaceutical market through digitalization, ensuring safe and efficient delivery of health products and services at fair and transparent prices [1][2] - The company operates with the mission of making quality medical products accessible to all, enhancing the overall efficiency of the healthcare ecosystem [1] Industry Characteristics - The pharmaceutical distribution industry in China has three main characteristics: low industry concentration, slow digitalization and information technology progress, and the need for improved service capabilities among retail terminals [2] - The implementation of the "two-invoice system" has accelerated industry concentration and raised competition barriers, increasing demands on companies regarding financial strength, operational efficiency, warehousing, distribution capabilities, and after-sales service [2] Digital Transformation - Yaoshi Bang has developed a smart supply chain model to drive digital innovation in pharmaceutical transactions and services, proposing new ideas for the intelligent upgrade of the pharmaceutical distribution industry [2] - The company is recognized as a leader in the digital transformation of the out-of-hospital pharmaceutical and medical service market, connecting upstream (pharmaceutical companies and distributors) and downstream (pharmacies and grassroots medical institutions) through technology [2] Future Outlook - Looking ahead, Yaoshi Bang aims to leverage its industry experience and technological innovation to lead the digital transformation in the out-of-hospital pharmaceutical sector, enhancing operational efficiency across the industry chain [3] - As of the first half of 2025, the company reported an average of 453,000 active buyers per month, a year-on-year increase of 6.5%, with a payment rate of 94% and an average order quantity of 29.2 per paying buyer [3] - Yaoshi Bang has registered over 827,000 buyers, covering 98.9% of counties and 91.2% of townships nationwide [3]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期: 2025年12月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 20,000,000,000 | USD | 0.0000025 | USD | | 50,000 | | 增加 / 減少 (-) | | | | | | USD | | | | 本月底結存 | | | 20,000,000,000 | USD | 0.0000025 | USD | | 50,000 | ...

Core Insights - The latest shareholder equity disclosures for Baixinan-B (02185), Yaoshibang (09885), and Shiyao Group (01093) were conducted on November 25, 2025 [1] Group 1: Baixinan-B (02185) - Winning Powerful Limited increased its holdings from 45.7756 million shares to 45.7856 million shares, representing a holding percentage change from 19.42% to 19.43% [2] - Wang Philip Li also increased his holdings from 84.9577 million shares to 84.9677 million shares, with a holding percentage change from 36.04% to 36.05% [2] Group 2: Yaoshibang (09885) - Chen Fei increased his holdings from 9 million shares to 9.15 million shares, with a holding percentage change from 1.32% to 1.34% [2] Group 3: Shiyao Group (01093) - Cai Dongchen increased his holdings from 2.872 billion shares to 2.887 billion shares, with a holding percentage change from 24.93% to 25.06% [2]

香港联交所最新数据显示，11月24日，执行董事陈飞增持药师帮(09885)15万股，每股作价6.75港元，总 金额为101.25万港元。增持后最新持股数目为915万股，持股比例为1.34%。 ...

Group 1 - The executive director Chen Fei increased his stake in Yaoshibang (09885) by purchasing 200,000 shares at a price of HKD 6.964 per share, totaling approximately HKD 1.3928 million [1] - After the purchase, the total number of shares held by Chen Fei is approximately 9 million, representing a holding percentage of 1.32% [1]

智通财经APP获悉，香港联交所最新数据显示，11月20日，执行董事陈飞增持药师帮(09885)20万股，每 股作价6.964港元，总金额约为139.28万港元。增持后最新持股数目约为900万股，持股比例为1.32%。 ...

Core Insights - The latest shareholder equity disclosures for several companies, including Ajisen (China) (00538), Zai Lab Limited (09939), Yaoshi Bang (09885), and Kwansei Holdings (01925), were reported on November 21, 2025 [1] Group 1: Shareholder Changes - Ajisen (China) saw a complete divestment by Ren Yuwen, reducing holdings from 95,000 shares to 0 shares, resulting in a holding percentage change from 0.01% to 0% [2] - Zai Lab Limited had an increase in holdings by Tong Youzhi from 52,200,300 shares to 52,500,300 shares, with a holding percentage change from 11.15% to 11.21% [2] - Another increase in Zai Lab Limited was reported for KT International, which raised its holdings from 49,700,300 shares to 50,000,300 shares, changing the holding percentage from 10.62% to 10.68% [2] - Yaoshi Bang experienced a slight increase in holdings by Chen Fei from 8,800,000 shares to 9,000,000 shares, with a holding percentage change from 1.29% to 1.32% [2] - Kwansei Holdings reported an increase in holdings by Tian Dong from 3,895,400 shares to 4,443,400 shares, changing the holding percentage from 0.96% to 1.10% [2]

Core Viewpoint - The company, Yaoshi Bang (09885.HK), announced a share buyback of 200,000 shares at a cost of HKD 1.4 million on November 20 [1] Related Events - On November 20, Yaoshi Bang (09885.HK) executed a buyback of 200,000 shares for a total expenditure of HKD 1.4 million [1] - Executive director Chen Fei increased his stake by purchasing 200,000 shares [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 表格類別： 股票 狀態： 新提交 公司名稱： 藥師幫股份有限公司 (於開曼群島註冊成立之有限公司) 呈交日期： 2025年11月20日 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 09885 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包 ...

Core Viewpoint - The company, Yaoshi Bang (09885), announced that executive director Chen Fei purchased a total of 200,000 shares in the open market on November 20, 2025, indicating confidence in the company's future and growth potential, as well as a long-term commitment to the company [1] Summary by Relevant Sections - **Share Purchase** - Executive director Chen Fei acquired 200,000 shares in the open market [1] - **Management Confidence** - The board of directors believes that the share purchase reflects Chen's confidence in the company's prospects and growth potential [1] - **Long-term Commitment** - The share acquisition demonstrates Chen's long-term commitment to the company [1]